Steven Arkin

Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A -- Safety, Efficacy, and Development of Inhibitors

Jeanne M. Lusher, Steven Arkin, Charles F. Abildgaard et al. · New England Journal of Medicine · 1993 · 494 citations · Full text

Medicine, Hematology, Infectious Diseases +14

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

Jörge E. Cortes, Hagop M. Kantarjian, Tim H. Brümmendorf et al. · Blood · 2011 · 461 citations

Life Sciences, Hematology, Oncology +9

Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides—Harmonized Terminology and Tactical Recommendations

Ganesh M. Shankar, Steven Arkin, Laurent Cocea et al. · The AAPS Journal · 2014 · 339 citations · Full text

Life Sciences, Clinical Sciences, Immunology +17

Human Recombinant DNA–Derived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia A

Richard S. Schwartz, Charles F. Abildgaard, Louis M. Aledort et al. · New England Journal of Medicine · 1990 · 266 citations

Medicine, Biotechnology, Hematology +12

Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A

Jeanne M. Lusher, Steven Arkin, C. F. ABILGAARD et al. · Survey of Anesthesiology · 1993 · 182 citations

Medicine, Hematology, Hemostasis +12